Holen Sie sich die Stockscreener-App
0.00
100.00%
-54.65
Schlusskurs vom Vortag:
$54.65
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$4.50B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
0.00
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Firmenname
Akero Therapeutics Inc
Sektor
Branche
Telefon
650-487-6488
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Vergleichen Sie AKRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
0.00 | 4.50B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.96 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.36 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
851.42 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.17 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
200.67 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-04 | Eingeleitet | TD Cowen | Buy |
| 2025-01-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-18 | Eingeleitet | Citigroup | Buy |
| 2024-04-22 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Eingeleitet | Guggenheim | Buy |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-15 | Eingeleitet | Jefferies | Buy |
| 2019-07-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Medical Stocks To Add to Your WatchlistDecember 15th - MarketBeat
Best Medical Stocks To Follow TodayDecember 12th - MarketBeat
Promising Mid Cap Stocks To Watch NowDecember 11th - MarketBeat
Top Mid Cap Stocks To Follow NowDecember 12th - MarketBeat
Hudson Bay Capital Management LP Buys 84,573 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Frazier Life Sciences Management L.P. Acquires New Shares in Akero Therapeutics, Inc. $AKRO - MarketBeat
Hudson Bay Capital Management LP Acquires 84,573 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Best Medical Stocks To Follow NowDecember 10th - MarketBeat
General Atlantic L.P. Acquires 500,000 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Bellevue Group AG Grows Stake in Akero Therapeutics, Inc. $AKRO - MarketBeat
Alkeon Capital Management LLC Grows Stake in Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics, Inc. $AKRO Stake Lowered by Redmile Group LLC - MarketBeat
Liver Fibrosis Market Expected to Gain Momentum Through 2034, According to DelveInsight | Madrigal Pharma, Akero Therapeutics, Sagimet Biosciences, Boehringer Ingelheim, Zealand Pharma, 89bio - Barchart.com
HighVista Strategies LLC Acquires 35,926 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors - ts2.tech
Akero Therapeutics' (AKRO) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Novo Nordisk seals acquisition of Akero Therapeutics - medwatch.com
Stempoint Capital LP Reduces Stock Position in Akero Therapeutics, Inc. $AKRO - MarketBeat
Novo Nordisk concludes USD 4.7 billion acquisition of Akero Therapeutics - Medical Dialogues
Novo Nordisk A/S (CPSE: NOVO B) completed the acquisition of Akero Therapeutics, Inc.. - marketscreener.com
Novo Nordisk Concludes Up to $5.2 Billion Takeover of Akero Therapeutics - marketscreener.com
Akero Therapeutics completes merger with Novo Nordisk, delists from Nasdaq By Investing.com - Investing.com Canada
Akero Therapeutics Announces Merger and Delisting Plans - TipRanks
Akero Therapeutics completes merger with Novo Nordisk, delists from Nasdaq - Investing.com
Novo Nordisk buys Akero Therapeutics in $5.2B deal - breakingthenews.net
Novo Nordisk completes $4.7 billion acquisition of Akero Therapeutics By Investing.com - Investing.com Canada
Novo Nordisk completes $4.7 billion acquisition of Akero Therapeutics - Investing.com
Vivo Capital LLC Buys 233,521 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics Announces Board and Executive Changes Following Merger - TradingView — Track All Markets
Novo Nordisk completes acquisition of Akero Therapeutics - marketscreener.com
Novo Nordisk has completed its acquisition of Akero Therapeutics - GlobeNewswire
Akero Therapeutics announces merger and delisting plans - MSN
(AKRO) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Aug Mood: Why Akero Therapeutics Inc stock could benefit from AI revolution2025 Market WrapUp & Technical Pattern Based Buy Signals - moha.gov.vn
Akero Therapeutics, Inc. $AKRO Stock Holdings Lessened by Marshall Wace LLP - MarketBeat
JPMorgan Chase & Co. Sells 18,890 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics, Inc. $AKRO Position Boosted by Schroder Investment Management Group - MarketBeat
Akero Therapeutics, Inc. $AKRO Shares Sold by Russell Investments Group Ltd. - MarketBeat
Is Akero Therapeutics Inc. (0K4) stock a contrarian opportunity2025 Market Outlook & Low Risk Profit Maximizing Plans - Newser
Will Akero Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - Newser
What dividend safety rating applies to Akero Therapeutics Inc. (0K4) stockWeekly Market Outlook & Weekly Stock Performance Updates - Newser
Can Akero Therapeutics Inc. (0K4) stock deliver strong annual returnsWeekly Stock Analysis & Daily Price Action Insights - Newser
Novo Nordisk greenlighted by German antitrust authorities to acquire Akero - medwatch.com
Novo Nordisk wins German approval to buy Akero Therapeutics - MLex
Germany's cartel office says it approved acquisition of Akero Therapeutics by Novo Nordisk - marketscreener.com
Key facts: Novo Nordisk launches Ozempic in India; Dr Reddy's court nod; Akero acquisition approved - TradingView
Novo Nordisk-Akero Therapeutics deal gets green light in US - MLex
Akero Therapeutics shareholders approve acquisition by Novo Nordisk - Investing.com Nigeria
Akero Therapeutics stockholders approve acquisition by Novo Nordisk - marketscreener.com
Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akero Therapeutics Inc-Aktie (AKRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Young Jonathan | Chief Operating Officer |
Nov 24 '25 |
Option Exercise |
23.13 |
12,550 |
290,333 |
209,448 |
| Yale Catriona | Chief Development Officer |
Nov 04 '25 |
Option Exercise |
24.19 |
8,266 |
199,983 |
74,800 |
| Cheng Andrew | President and CEO |
Oct 10 '25 |
Option Exercise |
19.87 |
30,000 |
596,100 |
556,114 |
| Cheng Andrew | President and CEO |
Oct 10 '25 |
Sale |
53.98 |
30,000 |
1,619,340 |
526,114 |
| Graham G. Walmsley | Director |
Oct 08 '25 |
Option Exercise |
20.55 |
90,832 |
1,866,155 |
93,000 |
| Rolph Timothy | Chief Scientific Officer |
Oct 07 '25 |
Option Exercise |
28.35 |
12,500 |
354,375 |
179,071 |
| Rolph Timothy | Chief Scientific Officer |
Oct 07 '25 |
Sale |
46.08 |
12,500 |
576,001 |
166,571 |
| Cheng Andrew | President and CEO |
Oct 08 '25 |
Option Exercise |
0.61 |
52,212 |
32,110 |
526,114 |
0.39%
1.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):